RGC.US Regencell Bioscience Holdings Ltd

Healthcare Biotechnology USA Stocks
4.72 USD
Close of Nov 17, 2026
4.38 69.00
Market cap
USD 2.34B
P/E
-
P/B
182.39x
ROE
-191.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is RGC.US undervalued?

Graham number

The Graham number of Regencell Bioscience Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regencell Bioscience Holdings Ltd fundamental analysis

No fundamental analysis for Regencell Bioscience Holdings Ltd yet.

Regencell Bioscience Holdings Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Full company profile